GOG-263: Randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy,
Role: PI,
Southwest Oncology Group,
(09/2024 - 09/2025)
Status: Approved
Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors,
Role: Investigator,
Southwest Oncology Group,
(01/2024 - 01/2025)
Status: Approved
SWOG / NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer,
Role: PI,
Southwest Oncology Group,
(12/2019)
Status: Completed
NRG-GY018, A Phase Ill Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage Ill or IVA, Stage IVB or Recurrent Endometrial Cancer (NCT # 03914612) (09/24/2019),
Role: PI,
Southwest Oncology Group,
(02/2024)
Status: Completed
Internal
Investigator initiated CIPNGRASP: A pilot study of intraneural facilitation for managing chemotherapy-induced peripheral neuropathy,
Role: Investigator,
LLU Dept. of Medicine,
(05/2024 - 05/2025)
Status: Approved
The impact of air pollution on gynecologic malignancies,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
(05/2024)
Status: Approved
Percutaneous Nephrostomy Complications in Gynecologic Cancers,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
(05/2024)
Status: Approved
Investigator Initiated – Retrospective Chart Review: Substance Use in Patients with Cervical Cancer,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
(03/2024)
Status: Approved
Investigator initiated: Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in breast and gynecologic-oncology patients: A prospective, randomized, open-label study,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(02/2024 - 02/2025)
Status: Approved
GCAT 2024 - Reversing Chemoresistance in Organoid and Patient-Derived Xenograft Models of Ovarian Cancer,
Role: PD/PI,
LLU School of Medicine,
(01/2024 - 12/2025)
Status: Awarded
Exploring hormone replacement therapy in those who have undergone treatment for gynecologic cancers,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
(02/2022)
Status: Approved
Incidence and Outcomes of Cervical Cancer Cases at a Rural Hospital in Malawi,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
(01/2022)
Status: Approved
Reversing Chemoresistance in Recurrent Ovarian Cancer,
Role: PD/PI,
LLU School of Medicine,
(01/2022 - 12/2024)
Status: Awarded
Efficacy of Ultrasound Guided Transversus Abdominis Plane (TAP) Block in Robotic Gynecological Oncology Procedures: A Retrospective Review,
Role: Investigator,
LLU Dept. of Anesthesiology,
(12/2021)
Status: Approved
Investigator Initiated - Should Routine Appendectomy Be Performed During Open Gynecologic Oncology Surgery?,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(09/2021)
Status: Approved
Impact of COVID-19 pandemic on cancer screening and follow up,
Role: Investigator,
LLU Dept. of Surgery,
(12/2020)
Status: Approved
Investigator initiated- Retrospective chart review: Addition of spinal anesthesia to general anesthesia for reduction of postoperative pain and length of stay in open gynecologic oncology cases,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(10/2020 - 09/2021)
Status: Completed
MRI, Sonographic Findings, Delivery Outcomes, and the Risk of Accreta Development.,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(02/2020)
Status: Approved
Investigator initiated retrospective analysis of resuscitative Endovascular Balloon Occlusion (REBOA) use in placental disorder to minimize blood loss and other morbidities,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
(09/2019)
Status: Approved
Investigator initiated: Retrospective analysis to determine the incidence of Occult Cervical cancer in patients with Adenocarcinoma in situ at LLU,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
(02/2019)
Status: Approved
Improving genetic testing rates to enable targeted therapy: Novel combination therapy targeting Snail and PARP for advanced ovarian cancer in Hispanic women,
Role: PD/PI,
LLU School of Medicine,
(01/2018 - 12/2021)
Status: Closed
Sexual and marital dysfunction in women with gynecologic cancer,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
(06/2015 - 06/2016)
Status: Completed
Development of a metastatic ovarian cancer patient-derived xenograft model,
Role: PD/PI,
LLU School of Medicine,
(01/2015 - 12/2016)
Status: Closed
Compassionate use of everolimus: Individual patient program (IPP) for treatment of recurrent progressive clear cell endocervical cancer with everolimus,
Role: PI,
LLU Dept. of Gynecology & Obstetrics,
Status: Completed
Non-Profit Organization
Improving genetic testing rates for ovarian cancer precision medicine: Combination therapy targeting Snail and PARP1 in ovarian cancer subtypes,
Role: Co-PD/PI,
Mary Kay Foundation,
(07/2018 - 06/2020)
Status: Closed
State
Targeting cancer stem cells to prevent recurrence and metastasis of ovarian cancer,
Role: Co-Investigator,
California Institute for Regenerative Medicine,
(03/2018 - 02/2020)
Status: Closed